Bracco's new ultrasound contrast agent in trials:
This article was originally published in Clinica
Executive Summary
Bracco is developing a new ultrasound contrast agent, BR14, which could provide doctors with more time to visualise the liver, kidneys, and possibly the heart, said the Milan, Italy-based company. Results from a 30-patient, phase I trial presented at last week's European Congress of Radiology meeting in Vienna, have shown that BR14 is a safe, effective agent in the kidneys and liver. Phase II trials are currently underway.